Navigation Links
China Sky One Medical, Inc. CFO to Present at Roth Conference
Date:2/6/2009

HARBIN, China, Feb. 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), today announced that the Company's Chief Financial Officer, Mr. Yu-bo (Stanley) Hao, will present and conduct one-on-one meetings at the upcoming Roth 21st Annual OC Growth Stock Conference in Dana Point, California.

    The date and time of China Sky One Medical's presentation are as follows:

    Date:    Tuesday, February 17, 2009
    Time:    3:00 p.m. Pacific Time
    Venue:   Track 5
             The Ritz Carlton Laguna Niguel
             One Ritz-Carlton Drive
             Dana Point, California 92629
    Webcast:http://www.wsw.com/webcast/roth20/cski/

A replay of the presentation will be available for 90 days following the live presentation using the same link and will also be available on the Company's website.

The ROTH 21st Annual OC Growth Stock Conference will feature presentations from over 200 growth companies. This event is designed to provide investors with a unique opportunity to gain insight into leading companies across all sectors. Additionally, there will be a special track dedicated to companies based in China. Presentations will provide a brief overview of the company's operations, and speakers will spend the majority of their time discussing topics that will highlight the value and investment opportunity their company represents.

Interested parties and investors may find more information about the conference by contacting conference@roth.com or calling (800) 933-6830.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR"), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Yu-Bo (Stanley) Hao, CFO
     Tel:   +86-451-5399-4069
     Email: china_sky_one@yahoo.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:     +1-646-213-1915
     Email:   crocker.coulson@ccgir.com
     Website:http://www.ccgirasia.com

'/>"/>
SOURCE China Sky One Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
2. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
3. China-Biotics, Inc. Receives Manufacturing Certificate for New Products
4. China Biologic Products Enters into Short-Term Loan Agreement
5. China Pharma Holdings, Inc. Receives SFDA Production Approval for Tiopronin Enteric-Coated Capsules
6. American Oriental Bioengineering to Participate in the 2009 UBS Greater China Conference
7. China Sky One Medical, Inc. Qualifies for Preferential Income Tax Rate
8. Health Robotics Announces Partnership in the Peoples Republic of China With The Devon International Group
9. China Sky One Medical, Inc. Receives Scientific Achievement Award
10. China Medicine to Distribute Dental and Surgical Instruments
11. HUYA Bioscience Announces Agreement to Provide Schering-Plough With Drug Development Candidates From China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:5/9/2016)... -- Elevay is currently known as the ... high net worth professionals seeking travel for work   ... there is still no substitute for a face-to-face meeting. ... deal with a firm handshake. This is why wealthy ... citizenship via investment programs like those offered by the ...
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
Breaking Biology News(10 mins):